DUBLIN, Jan. 31, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today launches a new multi-channel direct-to-consumer campaign for CoolSculpting, titled "Not Cool vs. Cool," which includes a national traditional and digital media effort and two new brand ambassadors: figure skating superstar Johnny Weir and elite golfer Ian Poulter. CoolSculpting is the only FDA-cleared, non-surgical treatment to freeze away stubborn fat.

The "Not Cool vs Cool" campaign takes a lighthearted approach to extreme fat-loss methods and juxtaposes the 'cool' proven CoolSculpting treatment with these 'not cool' fictitious, fat-loss methods.

"With more than six million treatments worldwide to date1 and 40 percent brand awareness2, CoolSculpting is well-positioned to be a treatment of choice for the 88 percent of consumers concerned with excess body fat in specific areas3," said Michael Jafar, Vice President, Medical Aesthetics Body Contouring, Allergan. "In addition, data shows that of the 35 million consumers expressing interest in CoolSculpting, more than 46 percent are male4. CoolSculpting has a unique opportunity with male consumers and our campaign will target them as well."

To that end, CoolSculpting is partnering with Weir and Poulter, known for embodying "cool" on the ice and the green, to support awareness campaigns via their respective digital video series, online assets and media events. Both Weir and Poulter have had CoolSculpting treatments.

"As a professional figure skater, I'm an active person and do my best to follow a healthy diet," said Weir. "CoolSculpting is ideal for people like me who make a healthly lifestyle a priority but need a little help targeting stubborn fat that's resistant to diet and exercise."

"I'm fortunate to have a beautiful family and incredible career though, as you can imagine, these priorities mean I have very little free time," said Poulter. "With treatment times as short as 35 minutes, CoolSculpting fit into my hectic schedule and didn't entail the long recovery period that some surgical procedures require."

References

1 Data on File Allergan, Inc.

2 Quintessent CoolSculpting Consumer Awareness and Marketing Sizing, July 2017. Note: Surveyed = US 18-75, HHI > $35K; N = 2501 (weighted); Quintessent Marketing analysis November 2017

3 American Society for Dermatologic Surgery Consumer Survey on Cosmetic Dermatologic Procedures, 2017

4 Quintessent Consumer Awareness, December 2017. Note: Surveyed = US 18-75, HHI > $35K; N = 2501 (weighted); Quintessent Marketing analysis November 2017

About the CoolSculpting® Treatment

CoolSculpting is a non-surgical, clinically proven treatment that selectively reduces unwanted fat using a patented cooling technology. Cleared by the FDA, CoolSculpting works by gently cooling targeted fat cells in the body to induce a natural, controlled elimination of fat cells without affecting surrounding tissue, and the treated fat cells are gone for good. Millions of CoolSculpting treatments have been performed in more than 80 countries. CoolSculpting is available through a network of CoolSculpting Centers worldwide. Dermatologists, plastic surgeons and aesthetic specialists that offer CoolSculpting can be found at www.coolsculpting.com.

In the U.S., the CoolSculpting procedure is FDA-cleared for the treatment of visible fat bulges in the submental area, thigh, abdomen and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll), and upper arm. It is also FDA-cleared to affect the appearance of lax tissue with submental area treatments.

During the procedure you may experience sensations of pulling, tugging, mild pinching, intense cold, tingling, stinging, aching, and cramping at the treatment site. These sensations subside as the area becomes numb. Following the procedure, typical side effects include temporary redness, swelling, blanching, bruising, firmness, tingling, stinging, tenderness, cramping, aching, itching, or skin sensitivity, and sensation of fullness in the back of the throat after submental area treatment. Rare side effects may also occur. The CoolSculpting procedure is not for everyone. You should not have the CoolSculpting procedure if you suffer from cryoglobulinemia, cold agglutinin disease, or paroxysmal cold hemoglobinuria. The CoolSculpting procedure is not a treatment for obesity. Please see full Important Safety Information for additional information.

Be sure to follow CoolSculpting on Facebook, Twitter, Pinterest and YouTube.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 55+ mid-to-late stage pipeline programs currently in development.

Allergan's success is powered by our more than 18,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; uncertainty associated with financial projections, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended September 30, 2017. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS:

Allergan:

Investors:

Daphne Karydas

(862) 261-8006

Media:

Lisa Brown

(862) 261-7320

Marlo Rodman

(925) 918-1190

SOURCE Allergan plc

Related Links

www.allergan.com

